• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Contineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8/13/24 4:10:32 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTNM alert in real time by email
    cont20240719c_8k.htm
    false 0001855175 0001855175 2024-06-30 2024-06-30

     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

    FORM 8-K
     

     
    CURRENT REPORT
     
    Pursuant to Section 13 OR 15(d) of  the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): August 13, 2024
     

     
    Contineum Therapeutics, Inc.
    (Exact name of registrant as specified in its charter)
     

     
     
     
             
    Delaware
     
    001-42001
     
    27-1467257
    (State or other jurisdiction
    of incorporation)
     
    (Commission
    File Number)
     
    (IRS Employer
    Identification No.)
     
    10578 Science Center Drive, Suite 200
    San Diego, California 92121
    (Address of principal executive offices, including zip code)
     
    (858) 333-5280
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former name or former address, if changed since last report)
     

     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act:
     
    Title of each class
     
    Trading Symbol(s)
     
    Name of each exchange on which registered
    Class A Common Stock, par value $0.001 per share
     
    CTNM
     
    The Nasdaq Global Market LLC
    (Nasdaq Global Select Market)
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company          ☒
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
     


     

     
     
     
    Item 2.02 Results of Operations and Financial Condition.
     
    On August 13, 2024, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing, among other items, the Company’s financial results for the quarter ended June 30, 2024 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.
     
    The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section and will not be incorporated by reference into any registration statement filed by the Company, under the Securities Act of 1933, as amended, unless specifically identified as being incorporated therein by reference.
     
    Item 7.01 Regulation FD Disclosure.
     
    Corporate Presentation.
     
    On August 13, 2024, the Company provided an update to its corporate presentation by posting the presentation to the Company’s website, www.contineum-tx.com. The Company plans to use its website to disseminate future updates to its corporate presentation and does not intend to file or furnish a Form 8-K alerting investors each time the presentation is updated.
     
    The information set forth in this Item 7.01 is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or under the Exchange Act, whether made before or after the date hereof, except as expressly provided by specific reference in such a filing.
     
    By filing this Current Report on Form 8-K and furnishing the information in this Item 7.01, the Company makes no admission as to the materiality of Item 7.01 in this report or the presentation available on the Company’s website. The information contained in the corporate presentation is summary information that is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this Current Report on Form 8-K, although it may do so from time to time as its management believes is appropriate or as required by applicable law. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, by updating its website or through other public disclosure.
     
    Item 9.01 Financial Statements and Exhibits.
     
    (d)  Exhibits.
     
    Exhibit
    No.
     
    Description
         
    99.1
     
    Press release dated August 13, 2024.
         
    104
     
    Cover Page Interactive Data File (embedded within XBRL document).
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Dated: August 13, 2024
     
         
    Contineum Therapeutics, Inc.
       
    By:
     
     /s/ Peter Slover
       
    Peter Slover
       
    Chief Financial Officer
    Principal Financial Officer and Principal Accounting Officer
     
     
    Get the next $CTNM alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTNM

    DatePrice TargetRatingAnalyst
    1/8/2026$14.00Overweight → Equal-Weight
    Morgan Stanley
    11/13/2025$22.00Outperform
    Leerink Partners
    9/25/2025$20.00Outperform
    Leerink Partners
    6/20/2025Outperform
    William Blair
    10/22/2024$32.00Outperform
    Robert W. Baird
    More analyst ratings

    $CTNM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Contineum Therapeutics downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Contineum Therapeutics from Overweight to Equal-Weight and set a new price target of $14.00

    1/8/26 8:37:44 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Contineum Therapeutics with a new price target

    Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $22.00

    11/13/25 9:09:54 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Contineum Therapeutics with a new price target

    Leerink Partners initiated coverage of Contineum Therapeutics with a rating of Outperform and set a new price target of $20.00

    9/25/25 8:29:14 AM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lorrain Daniel S.

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    4/6/26 5:43:32 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Lorrain Daniel S. sold $62,585 worth of shares (4,170 units at $15.01), decreasing direct ownership by 3% to 151,882 units (SEC Form 4)

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    3/2/26 6:30:02 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CMO & Head of Development Watkins Tim exercised 3,611 shares at a strike of $4.50 and sold $54,220 worth of shares (3,611 units at $15.02) (SEC Form 4)

    4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)

    3/2/26 6:28:58 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $CTNM
    SEC Filings

    View All

    Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on March 12, 2026 (Grant Date), the Compensation Committee of the Company's Board of Directors granted an inducement award consisting of a non-qualified stock option to purchase 51,000 shares of Class A common stock to one new non-executive employee under the Company's 2026 Employment Inducement Equity Incentive Plan. The award was granted as an inducement material to the new employee's employment with the Company in accordance with Nasdaq L

    3/13/26 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones

    - Patient dosing initiated in PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF) - Topline data from the exploratory PIPE-791 Phase 1b trial in patients with chronic pain is expected in the second quarter of 2026 Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2025 financial results and affirmed its key clinical development milestones. "We're off to a strong start in 2026, having recently dosed t

    3/5/26 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Leerink Partners Global Healthcare Conference on Wednesday, March 11th at 2:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies

    3/3/26 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by Contineum Therapeutics Inc.

    SCHEDULE 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

    4/17/26 4:42:47 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Contineum Therapeutics Inc.

    S-8 - Contineum Therapeutics, Inc. (0001855175) (Filer)

    3/5/26 4:18:32 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Contineum Therapeutics Inc.

    424B5 - Contineum Therapeutics, Inc. (0001855175) (Filer)

    3/5/26 4:15:43 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Leadership Updates

    Live Leadership Updates

    View All

    Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Timothy Watkins, M.D., M.Sc., to the Company's executive team as its Chief Medical Officer and Head of Development. Effective immediately, Dr. Watkins will lead all clinical development and medical affairs activities at Contineum. Dr. Watkins succeeds Stephen L. Huhn, M.D., who has been the Company's Chief Medical Officer since early 2020. Dr. Huhn will serve as an advisor during the leadership transition. "We're excited for D

    4/28/25 4:05:00 PM ET
    $CTNM
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

    Contineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. "We are excited to welcome Diego to our board," commented Eef Schimmelpennink, Contineum's Chairperson. "He has successfully led the development of novel therapies throughout his distinguished career and has an extensive track record in both early stage research and all stages of clinical development. During his time at Janssen Research, Dr.

    3/17/25 4:05:00 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company's Board of Directors

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients with inflammatory and immunological diseases, today announced the appointment of Lori Lyons-Williams as chair of its board of directors, succeeding William Rieflin, who stepped down from the board effective January 3, 2025. Mr. Rieflin will remain as a consultant for the company. "We are pleased to welcome Lori as chair of the board," said Brian Wong, M.D., Ph.D., President and CEO of RAPT. "In the four years that Lori has served as a board membe

    1/6/25 8:00:00 AM ET
    $CTNM
    $RAPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CTNM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Contineum Therapeutics Inc.

    SC 13G - Contineum Therapeutics, Inc. (0001855175) (Subject)

    11/14/24 4:38:16 PM ET
    $CTNM
    Biotechnology: Pharmaceutical Preparations
    Health Care